pubmed.ncbi.nlm.nih.gov

The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review - PubMed

Review

. 2023 Mar;79(3):371-381.

doi: 10.1007/s00228-023-03454-y. Epub 2023 Jan 26.

Affiliations

Review

The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review

Ehsan Motaghi et al. Eur J Clin Pharmacol. 2023 Mar.

Abstract

Purpose: Previous studies have shown that tetrahydrocannabinol (THC), the main psychoactive component of cannabis, can impair cognitive abilities. There is also some evidence that cannabidiol (CBD), the most abundant non-intoxicating constituent of cannabis, can attenuate these effects. The purpose of this study was to investigate the effects of THC:CBD oromucosal spray (with equal parts THC and CBD) on cognition compared with control conditions in human studies.

Methods: A systematic literature search was performed on four major bibliographic databases. Studies were included in the present review if they evaluated the cognitive effects of THC:CBD oromucosal spray compared with a control condition.

Results: Ten studies were identified (7 on patients with multiple sclerosis, 1 on those with Huntington, and 2 on healthy volunteers) with 510 participants in total. There was considerable heterogeneity among the studies in terms of dose and duration of administration. All studies have used an equal or nearly equal dose of THC and CBD.

Conclusions: Although the results across studies were somewhat inconsistent, most evidence revealed that there is no significant difference between THC:CBD oromucosal spray and control treatments in terms of cognitive outcomes. However, more trials are needed with longer follow-up periods, and dose considerations, particularly comparing lower and higher doses of the spray.

Keywords: Cannabidiol; Cannabinoid; Multiple sclerosis; Nabiximols; Sativex.

© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Crean RD, Crane NA, Mason BJ (2011) An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med 5(1):1 - PubMed - PMC - DOI
    1. Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, Bloomfield MA, Curran HV, Baler R (2016) Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiat 73(3):292–297 - DOI
    1. Wright MJ Jr, Vandewater SA, Taffe MA (2013) Cannabidiol attenuates deficits of visuospatial associative memory induced by Δ9tetrahydrocannabinol. Br J Pharmacol 170(7):1365–1373 - PubMed - PMC - DOI
    1. Curran VH, Brignell C, Fletcher S, Middleton P, Henry J (2002) Cognitive and subjective dose-response effects of acute oral Δ9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology 164(1):61–70 - PubMed - DOI
    1. Schoedel AK, Jane Harrison S (2012) Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols): potentials and limitations for psychosis research. Curr Pharm Des 18(32):5008–5014 - PubMed - DOI

Publication types

MeSH terms

Substances

LinkOut - more resources